Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Control Bionics Ltd
CBLControl Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; and NeuroNode Duo, a wireless sensor. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia. Address: 11-13 Pearson Street, Cremorne, VIC, Australia, 3121
Analytics
Precio Objetivo de WallStreet
0.091 AUDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave CBL
Análisis de dividendos CBL
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout CBL
Valoración de la acción CBL
Finanzas CBL
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |